BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 8996560)

  • 1. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
    Babusíková O; Glasová M; Koníková E; Kusenda J
    Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
    Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
    Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
    Zelezníková T; Babusíková O
    Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative immunocytofluorometry--new parameters for the definition of leukemia cells.
    Babusíková O; Glasová M; Stasáková J; Kusenda J; Koníková E
    Neoplasma; 1997; 44(6):348-55. PubMed ID: 9605006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifts in expression of immunological cell markers in relapsed acute leukemia.
    Tomová A; Babusíková O
    Neoplasma; 2001; 48(3):164-8. PubMed ID: 11583283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
    Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
    Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
    Drach J; Drach D; Glassl H; Gattringer C; Huber H
    Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance.
    Bahia DM; Yamamoto M; Chauffaille Mde L; Kimura EY; Bordin JO; Filgueiras MA; Kerbauy J
    Haematologica; 2001 Aug; 86(8):801-6. PubMed ID: 11522535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition of acute biphenotypic leukemia.
    Matutes E; Morilla R; Farahat N; Carbonell F; Swansbury J; Dyer M; Catovsky D
    Haematologica; 1997; 82(1):64-6. PubMed ID: 9107085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunophenotyping of acute leukemias: diagnostic and pronostic utility in Abidjan, Côte d'Ivoire].
    Inwoley KA; Sawadogo D; Mizero L; Salou M; Karim N; Sangaré A
    Bull Soc Pathol Exot; 2004; 97(5):319-22. PubMed ID: 15787262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic heterogeneity and aberrant markers expression in T-cell leukemia.
    Babusíková O; Glasová M; Koníková E; Kusenda J; Cáp J; Gyárfás J; Koubek K
    Neoplasma; 1998; 45(3):128-34. PubMed ID: 9717523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia of early B-cell phenotype.
    Mlcáková A; Babusíková O
    Neoplasma; 2003; 50(6):416-21. PubMed ID: 14689062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological classification of chronic myeloid leukemia distinguishes chronic phase, imminent blastic transformation, and acute lymphoblastic leukemia.
    Schmetzer HM; Gerhartz HH
    Exp Hematol; 1997 Jun; 25(6):502-8. PubMed ID: 9197328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
    Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
    Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia.
    Sartor M; Bradstock K
    Cytometry; 1994 Sep; 18(3):119-22. PubMed ID: 7813331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies.
    Macedo A; Orfão A; Gonzalez M; Vidriales MB; López-Berges MC; Martínez A; San Miguel JF
    Leukemia; 1995 Jun; 9(6):993-8. PubMed ID: 7596191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant markers expression in T- and B-lymphoid and myeloid leukemia cells of different differentiation stages.
    Babusíková O; Koníková E; Kusenda J; Koubek K
    Neoplasma; 1999; 46(5):277-82. PubMed ID: 10665842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia.
    Koníková E; Kusenda J; Babusíková O; Glasová M
    Neoplasma; 1995; 42(5):227-34. PubMed ID: 8552200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The analogy in cell immunophenotype and parameters of cell cycle of ectopic thymus, normal thymus, and some acute lymphoblastic leukemia of T-phenotype.
    Babusíková O; Tomová A
    Neoplasma; 2002; 49(5):312-8. PubMed ID: 12458329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.